Empagliflozin
Metabolic Dysfunction-Associated Steatohepatitis
Explore 128 assets in Metabolic Dysfunction-Associated Steatohepatitis →Floatz Rating
BB67/100
Confidence
Indicative
Sponsor
Badr University
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07180745CT.gov Empagliflozin Versus Statins in Non-Alcoholic Fatty Liver Disease | — | Not Yet Recruiting | — | — | — |
NCT06519448CT.gov Reducing Non-Alcoholic Steatohepatitis | — | Enrolling By Invitation | — | — | — |
NCT05605158CT.gov Comparative Clinical Study Between Empagliflozin Versus Pioglitazone in Non-diabetic Patients With Non-alcoholic Steatohepatitis | — | Unknown | — | — | — |
NCT05232071CT.gov Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus | — | Completed | — | — | — |
NCT04976283CT.gov Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty Liver | — | Unknown | — | — | — |
NCT04639414CT.gov Combined Active Treatment in Type 2 Diabetes with NASH | — | Active Not Recruiting | — | — | — |
NCT04702490CT.gov Study to Evaluate MET409 Alone or in Combination With Empagliflozin in Patients With Type 2 Diabetes and NASH | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Metabolic Dysfunction-Associated Steatohepatitis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Empagliflozin (this asset) | Badr University | Approved | BB · 67 |
| Resmetirom | City University of New York | P4 | BBB |
| Pentoxifylline | Al-Azhar University | P4 | BBB |
| Pioglitazone | Badr University | P4 | BBB |
| Firsocostat | Gilead Sciences | P2 | BBB |
| Montelukast | Tanta University | P4 | BBB |
| Alpha Tocopherol | Shanghai Jiao Tong University School of Medicine | P4 | BBB |
| Rosuvastatin | Beni-Suef University | P4 | BBB |
| Ezetimibe | University of Palermo | P4 | BBB |
+42 more in the Metabolic Dysfunction-Associated Steatohepatitis cohort
Other indications for Empagliflozin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Prediabetes Syndrome | — | P4 | BBB · 74 |
| Metabolic Dysfunction-Associated Steatotic Liver Disease | — | P4 | BBB · 73 |
| Type 2 Diabetes Mellitus | — | P4 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Empagliflozin in Metabolic Dysfunction-Associated Steatohepatitis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 9, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/empagliflozin-metabolic-dysfunction-associated-steatohepatitis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →